

**M. RITA I. YOUNG, Ph.D.**

Associate Chief of Staff for Research & Development (151)  
Ralph H. Johnson VA Medical Center  
109 Bee Street, Charleston, SC 29401  
Phone: (843) 789-6707  
e-mail: rita.young@med.va.gov

Professor of Medicine and Professor of Otolaryngology  
Medical University of South Carolina, SC 29425

**EDUCATION:**

- B.S. - 1973            Department of Biology/Physics  
                             S.U.N.Y. at Stony Brook, Stony Brook, NY
- M.S. - 1974            Department of Veterinary Medicine  
                             University of Idaho, Moscow
- Ph.D. - 1978           Department of Bacteriology and Public Health  
                             Washington State University, Pullman, WA

**RESEARCH AND PROFESSIONAL EXPERIENCE:**

- 1975-1978            Teaching Assistant, Department of Bacteriology  
                             Washington State University, Pullman, WA 99163
- 1978-1980            Post-Doctoral Fellow, Immunobiology Research Center  
                             University of Wisconsin, Madison, WI 53706
- 1980-1983            Assistant Professor  
                             Indiana University Center for Medical Education at Muncie  
                             Ball State University, Muncie, IN 47306
- 1983-1986            Associate Professor  
                             Indiana University Center for Medical Education at Muncie  
                             Ball State University, Muncie, IN 47306
- 1985-1986            Visiting Research Scientist, Pathology Research  
                             Hines VA Hospital, Hines, IL 60141
- 1986-1989            Research Health Scientist, Pathology Research  
                             Hines VA Hospital, Hines, IL 60141
- 1986-1993            Associate Professor, Department of Pathology  
                             Loyola University Stritch School of Medicine, Maywood, IL 60153
- 1989-1998            Research Career Scientist  
                             Hines VA Hospital, Hines, IL 60141
- 1993-2003            Professor of Pathology  
                             Loyola University Stritch School of Medicine, Maywood, IL 60153

1994-2003	Professor of Otolaryngology and Director of Otolaryngology Research Loyola University Stritch School of Medicine, Maywood, IL 60153
1995-2003	Full Member of the Graduate Faculty Loyola University Stritch School of Medicine, Maywood, IL 60153
1999-2003	Senior Research Career Scientist Hines VA Hospital, Hines, IL 60141
1998-2003	Associate Chief of Staff for Research Hines VA Hospital, Hines, IL 60141
2003-present	Associate Chief of Staff for Research & Development Ralph H. Johnson VA Medical Center, Charles, SC 29401
2003-present	Senior Research Career Scientist Ralph H. Johnson VA Medical Center, Charleston, SC 29401
2003-present	Professor of Medicine and of Otolaryngology Medical University of South Carolina, Charleston, SC 29425

## **RESEARCH SUPPORT:**

### **PAST FUNDING (P.I. is M. Rita I. Young, unless indicated):**

1. Delaware County Cancer Society, Inc., Muncie, Indiana.  
Stimulation of tumor rejection by anti-PGE<sub>2</sub> antibodies.  
January 1981 - December 1981. \$1,720.
2. Elsa U. Pardee Foundation, Midland, Michigan.  
Tumor detection by monitoring serum prostaglandin E<sub>2</sub> concentrations.  
January 1982 - December 1982. \$17,684.
3. Delaware County Cancer Society, Inc., Muncie, Indiana.  
Prevention of tumor metastasis with monoclonal anti-prostaglandin E<sub>2</sub> antibodies.  
June 1982 - November 1983. \$8,895.
4. American Lung Association, New York, New York.  
Controlling lung malignancies with indomethacin.  
July 1983 - June 1984. \$13,953.
5. Delaware County Cancer Society, Inc., Muncie, Indiana.  
Monitoring tumor development by quantitating serum prostaglandin E<sub>2</sub> Levels.  
January 1984 - June 1985. \$19,067.
6. American Lung Association of Indiana, Indianapolis, Indiana.  
Alveolar macrophage-mediated immunosuppression in mice bearing Lewis lung carcinoma.  
July 1985 - June 1986. \$8,943.
7. Public Health Service, Bethesda, Maryland. (CA45080)  
Prostaglandin E<sub>2</sub> promotes tumor dissemination.  
September 1985 - April 1988. \$115,706.

8. Public Health Service, Bethesda, Maryland.  
Tumor-induced suppression of alveolar macrophages.  
January 1986 - December 1987. \$47,653.
9. Medical Research Service, Veterans Administration, Washington D.C.  
The *in vitro* activation of macrophage suppressor cells.  
Co-Investigator: H. Terry Wepsic, M.D., 10% effort  
April 1986 - March 1987. \$49,470.
10. Oncology Center Grant, Loyola University Medical Center, Maywood, Illinois  
Prostaglandin E<sub>2</sub> promotes tumor dissemination.  
October 1987 - April 1988. \$18,925.
11. Medical Research Service, Veterans Administration, Washington D.C.  
Hematopoiesis and bone marrow suppressor cells in tumor bearers.  
Co-Investigator: H. Terry Wepsic, M.D., 10% effort  
April 1987 - March 1990. \$329,300.
12. Greenwich Pharmaceuticals, Ft. Washington, Pennsylvania.  
Mechanisms of action of anti-inflammatory compounds.  
May 1987 - Dec. 1992. \$244,000.
13. Public Health Service, Bethesda, Maryland.  
Prostaglandin E<sub>2</sub> promotes tumor dissemination.  
April 1988 - March 1992. Direct costs: \$190,544.
14. LyphoMed, Inc., Melrose Park, IL  
Effects of experimental compounds on macrophage secretion of TNF.  
Aug. 1991 - Jan. 1992. \$4,100 (contractual studies).
15. American Cancer Society, Illinois Division, Chicago, Illinois.  
Stimulation of the metastatic properties of tumor cells GM-CSF.  
August 1992 - January 1994. \$34,960
16. Public Health Service, Bethesda, Maryland.  
Myeloid differentiation therapy reduces suppressor cells.  
July 1990 - June 1994. Direct costs: \$230,380.
17. Medical Research Service, Veterans Administration, Washington, D.C.  
Stimulation of immune suppressor cells by myelopoiesis-inducing tumors.  
Oct. 1990 - March 1994. \$173,646.
18. The Alzheimer Foundation, Chicago, Illinois  
Microglial activation when regulation by prostaglandin E<sub>2</sub> becomes defective.  
December 1994 - March 1996. Direct costs: \$30,000.
19. Public Health Service, Bethesda, Maryland: RO1-CA45080  
Prostaglandin E<sub>2</sub> promotes tumor dissemination.  
July 1992 - April 1997. \$494,500.
20. Medical Research Service, Department of Veterans Affairs, Washington, D.C.  
Therapy to block lung cancer induction of immune suppressor cells.

- April 1994 - March 1997. \$230,000
22. Adrian Labs / Pharmacia Inc.  
Analyses for TNF- $\alpha$ .  
November 1992 – November 1998. \$11,500 (contractual studies).
  23. American Cancer Society, Atlanta, GA.  
Angiogenic factors produced by human head and neck cancers.  
July 1995 - June 1998. \$90,000  
Career Development Award - Dr. Guy J. Petruzzelli, Dept. Otolaryngology, Loyola Univ.  
Sponsor/Mentor: Dr. M. Rita I. Young
  24. Public Health Service, Bethesda, Maryland: RO1-CA48080  
Myeloid differentiation therapy to enhance immune stimulatory therapy.  
January 1995 - December 1998. \$366,269.
  25. Procter & Gamble University Exploratory Research Program  
The role of microglia in Alzheimer's disease.  
M. Prechel is PI, with M.R.I. Young as Co-Principal Investigator  
July 1996 - June 1999. \$150,000.
  26. Theodore & Vada Stanley Foundation  
Serotonergic-mechanisms of immune function in Schizophrenia and affective disorders.  
J. Kut is PI, with M.R.I. Young as co-Principal Investigator  
October 1997 - September 1999. \$99,320.
  27. Public Health Service, Bethesda, Maryland. R55 CA78262.  
Dendritic cell growth from suppressor cells of cancer patients  
August 1998 – September 2000 \$80,000 (pilot study)
  28. Medical Research Service, Department of Veterans Affairs, Washington, D.C.  
Therapy to enhance anti-cancer immune reactivity.  
April 1997 - March 31, 2002 \$505,200.
  29. Public Health Service, Bethesda, Maryland. R21-CA77208-1.  
Vitamin D<sub>3</sub> to reduce suppressor cells in cancer patients.  
April 1998 – March 2001 \$161,145
  30. Public Health Service, Bethesda, Maryland. RO1 GM56424.  
Mechanism of myeloid maturation arrest in burn sepsis  
R. Shankar is PI, with M.R.I. Young as co-Investigator  
May 1998 – April 2001 \$371,623.
  31. Department of Veterans Affairs, Washington, D.C. – REAP application  
Promotion of functional recovery following spinal cord injury.  
K. Jones and T Khan are PIs, with M.R.I. Young as co-Investigator.  
October 1998 – September 2001; \$225,500, M.R.I. Young; \$1,350,000 total.
  32. American Cancer Society, Illinois Division, Ind. #00-42  
Tumor-induced immune inhibitory CD34<sup>+</sup> cells resist apoptosis.  
R. Wrone-Smith is PI, with M.R.I. Young as co-Investigator.  
August 2000 – July 2001 \$49,516.

33. Public Health Service, Bethesda, Maryland. RO1-CA45080-10.  
Protein phosphatases-1 and -2A restrict tumor metastasis.  
May 1997 - April 2003 \$893,549.
34. Public Health Service, Bethesda, Maryland. R01 CA79768.  
Phosphatase regulation of tumor-induced angiogenesis.  
March 1999 – February 2003 \$475,939.
35. Kenwood Laboratories, Inc., Chicago, IL.  
Intracellular activities of anti-inflammatory experimental carbohydrates.  
June 1990 – June 2003. \$70,000 (contractual studies).

**CURRENT FUNDING SUPPORT (P.I. is M. Rita I. Young, unless indicated):**

1. Public Health Service, Bethesda, Maryland. 1RO1 CA85266  
Contribution of vasculogenesis to tumor vascularization.  
May 1, 2000 – April 30, 2005; \$810,000 direct costs.
2. Medical Research Service, Department of Veterans Affairs, Washington, D.C.  
*In situ*-activated immunotherapy to block post-surgical cancer recurrence  
April 2002 – March 2006; \$554,500
3. Public Health Service, Bethesda, Maryland. RO1 CA97813.  
Blocking angiogenesis by targeting PP-2A pathways.  
April 2003 – March 2008; \$1,023,500
4. Aventis Pharmaceuticals, Inc.  
Combination docetaxel plus vitamin D<sub>3</sub> as an immune therapy in animals bearing head  
and neck squamous cell carcinomas.  
January 2004 – December 2004 \$50,000
5. Clinical Sciences Research Service, Department of Veterans Affairs, Washington, D.C.  
Vitamin D differentiation-inducing therapy to enhance intratumoral anti-tumor immune  
reactivity  
October 1, 2004 – September 30, 2009; funding level not yet determined

**PENDING FUNDING SUPPORT (P.I. is M. Rita I. Young):**

none

**SERVICE & ADMINISTRATION:**

**PRIOR ADMINISTRATIVE ACTIVITIES**

1. Associate Chief of Staff for Research, Edward Hines, Jr. VA Hospital (1998-2003)
2. President of the Chicago Association for Research and Education in Science (1998-2003)
3. Director of Cancer Research Laboratories at Hines VA Hospital (1985-2003)
4. Director, Research Program for the Department of Otolaryngology, Loyola University  
(1995-2003)

5. Coordinator, Hines Annual Research Symposium: 1992, 1993, 1994, 1995, 1996, 1997, 1998, 1999, 2000, 2001, 2002.
6. Chair of VA VISN12 Research Council (2000-2003)

### **CURRENT ADMINISTRATIVE ACTIVITIES**

1. Associate Chief of Staff for Research, Ralph H. Johnson VA Medical Center (2003-present)
2. President of the Charleston Research Institute (2004-present)
3. Acting Director, Network Research Service Line (2004-present)

### **PRIOR COMMITTEE ACTIVITIES AT HINES VA**

1. Science Student Award Selection Panel; Member/Mentor (1986-2003)
2. Basic Scientist Position Review Panel (1988-2003)
3. Research Radiation Safety Officer (1989-1997)
4. Research Steering Committee (1990-1993)
5. Hines VA Hospital Study Group on Aging (1990-1993)
6. Research Safety Committee (1990-1995)
7. Hospital Radiation Safety Committee (1990-1997)
8. New Research Employee Orientation Panel (1991-1997)
9. Hospital Research & Development Committee (1991-2003)
10. Advisory Board for Biological Psychiatry Section (1992-1998)
11. Chair, Research & Development Committee, Hines VA Hospital (1996-1998)
12. Quality Improvement Team (1998-1999)
13. Medical Executive Committee (1998-2003)
14. Dean's Committee (1998-2003)
15. Chair, Executive Council of the Clinical Staff (1999 - 2000)
16. Executive Council of the Clinical Staff (2000-2003)
17. Hines Leadership Council (1999-2003)

### **PRIOR COMMITTEE ACTIVITIES AT LOYOLA UNIVERSITY SCHOOL OF MEDICINE:**

1. Neurosciences and Aging Institute Research Grant Review Committee (1994-1997)
2. Member of the Committee on Medical Student Admissions (1998-2001)
3. Research Funding Committee (1992-2002)
4. Member of the Internal Advisory Council of the Cardinal Bernardin Cancer Center (1999-2003)

### **CURRENT COMMITTEE ACTIVITIES AT RALPH H. JOHNSON VA (Currently unless indicated)**

1. VA Clinical Executive Board (2003-present)
2. VA Resource Allocation Board (2003-present)
3. Network Research Service Line (2003-present)

4. Research and Development Committee (2003-present)
5. VA Academic Partnership Council (2003-present)

### **CURRENT COMMITTEE ACTIVITIES AT MEDICAL UNIVERSITY OF SOUTH CAROLINA**

1. Executive Research Council (2003-present)
2. Associate Deans for Research Council (2003-present)

### **REVIEWER OF GRANT PROPOSALS.**

1. Illinois Cancer Council, Chicago, IL, 1990, 1992
2. Research Advisory Group (RAG B), Department of Veterans Affairs Central Office, Washington, D.C., 1990-1994.
3. VA Merit-Review Board for Immunology, 1993-1996
4. Experimental Therapeutics-2 Study Section, National Institutes of Health, ad-hoc 1995-1997, full member 1997-2001.
5. Special Reviewer, Experimental Therapeutics Study Section, Division of Research Grants, National Institutes of Health, 1991, 1992, 1996, 1997, 1998, 2001, 2002.
6. National Institutes of Health PO1 site visit team member, 1997.
7. Ad hoc reviewer for Department of Veterans Affairs grants, 1990-present
8. National Aeronautics and Space Administration, American Institute of Biological Sciences, Washington, D.C., 1993, 1996
9. US Army Medical Research and Materiel Command: Breast and Prostate Cancer Research Initiatives; Clinical and Experimental Therapeutics Study Sections (1997-present)
10. Department of Veterans Affairs Review Committee for Historically Black Colleges and Universities (1998-2003)
11. Department of Veterans Affairs Merit Review Medical Advisory Board (1998-2002)
12. Department of Veterans Affairs Oncology Merit Review Board (2002-2005)
13. Experimental Therapeutics-2 Study Section, National Institutes of Health (2003).
14. Cancer Immunology Immunopathology Study Section, National Institutes of Health (2003-present).
15. Department of Veterans Affairs Review Board for Clinical Research Centers of Excellence, 2004.

### **BOARD MEMBERSHIPS IN NATIONAL ORGANIZATIONS:**

1. Editorial Board for Cancer Immunology and Immunotherapy, Jan. 1998-Dec.2002
2. Editorial Board of Investigative Urology, 1998-2003
3. Editorial Review Panel for Otolaryngology – Head and Neck Surgery, 2002-present
4. Board member of the National Association of VA Research and Education Foundations (2002-2005)
5. Editorial Board for Cancer Immunology and Immunotherapy, Jan. 2003-Dec. 2006

### **JOURNAL REVIEWER:**

1. International Journal of Cancer
2. British Journal of Cancer
3. Cancer Research
4. Invasion and Metastasis
5. Journal of Immunology
6. Cancer Research
7. Journal of Leukocyte Biology
8. Laboratory Investigation
9. Archives of Pathology & Laboratory Medicine

**CURRENT MEMBERSHIPS IN PROFESSIONAL AND HONORARY SOCIETIES:**

1. American Association of Immunologists
2. American Association for Cancer Research
3. Reticuloendothelial / Leukocyte Biology Society
4. American Association for the Advancement of Science
5. Women in Cancer Research

**HONORS AND AWARDS:**

1. National Institutes of Health Research Service Award; 1978, 1979.
2. Japan Fellowship for Foreign Investigators; 1989.
3. Associate Research Career Scientist Award, Department of Veterans Affairs, Washington, D.C.; 1989-1994, 1994-1998.
4. Research Career Scientist Award, Department of Veterans Affairs, Washington, D.C.; 1998-1998.
5. Senior Research Career Scientist Award, Department of Veterans Affairs, Washington, D.C.; 1999-2006.

**TEACHING:**

**FORMAL CLASSROOM TEACHING RESPONSIBILITIES (1980-1985):**

1. Medical Microbiology: Medical Immunology and Medical Virology; Indiana University Center for Medical Education, Course taught each winter quarter during 1980-1985 to first year medical students.
2. General Immunology: (Bio 344) Undergraduate course taught each fall and spring quarter during 1980-1984 to Ball State University students majoring in Medical Technology.
3. Immunology: (Bio 544) Graduate immunology course taught each fall and spring quarter during 1980-1984 at Ball State University, Biology Department.
4. General Virology: (Bio 331) Undergraduate course taught each fall quarter during 1980-1983 at Ball State University, Biology Department.

5. Virology: (Bio 531) Graduate course taught each fall quarter during 1980-1983 at Ball State University, Biology Department.

**THESIS ADVISOR FOR COMPLETED GRADUATE STUDENT PROGRAMS  
(Ball State University):**

1. Jill A. Simmermaker: Prostaglandin E<sub>2</sub> regulates production of tumoristatic factors by macrophage like P388D1 cells. M.S., 1984.
2. Clayton E. Estep: The effect of indomethacin on the macrophage tumoristatic activity of tumor-bearing mice. M.S., 1984.
3. Cathy S. Hoover: The effects of tumor-derived prostaglandin E<sub>2</sub> on the tumoricidal activities of cytotoxic T lymphocytes. M.S., 1984.
4. Piruz Nahreini: Regulation of Lewis lung carcinoma cell growth by prostaglandins. M.S., 1984.
5. Elizabeth H. Wheeler: Natural killer cell activity in mice bearing Lewis lung carcinoma. M.S., 1985.
6. Roger A. Endicott: Immunoregulation of T-lymphocyte proliferative activity by alveolar macrophages from mice bearing Lewis lung carcinoma tumors. M.S., 1986.
7. Michael P. Mahan: The effects of vigorous physical exercise on the immune system. Ed.D., 1987.
8. Patrick Duffie: The functional assessment of pulmonary alveolar macrophages in mice bearing Lewis lung carcinoma. Ed.D., 1988.

**COMMITTEE ADVISOR OR MEMBER FOR COMPLETED DOCTORAL  
PROGRAMS AT LOYOLA UNIVERSITY:**

1. Advisor for doctoral candidates: Department of Cell Biology, Neurobiology and Anatomy  
Jodi Jackson, Ph.D. awarded 2002  
Lisa Shafer, Ph.D. awarded 2002
2. Member of graduate committees in the Department of Microbiology:  
Clive Landis, Ph.D. awarded 1989  
David Beno, Ph.D. awarded 1990  
Silvia Kiertscher, Ph.D. awarded 1990
3. Member of graduate committees in the Department of Molecular and Cellular Biochemistry:  
Jianyi Zhang, Ph.D. awarded 1992  
Mark Janulis, Ph.D. awarded 1997  
Anna Szpaderska, Ph.D. awarded 2000
4. Member of graduate committees in the Molecular Biology Program:  
Sanjay D'Souza, Ph.D. awarded 2002
5. Member of graduate committee in the Department of Cell Biology, Neuroscience and Anatomy

Doug Faunce, Ph.D. awarded 1998  
Meredith Kamradt, Ph.D. awarded 2000  
Meredith Gregory, Ph.D. awarded 2000

**OTHER PAST RESEARCH/TEACHING RESPONSIBILITIES AT  
HINES/LOYOLA:**

1. Mentor for Science Student Fellowship Awardees at the Hines VA Hospital:  
Michael Coogan (1988 - 1992)  
Yvonne Lozano (1988 - 1992)  
Anelka Djordjevic (1992 - 1996)  
Janet Benefield: (1995 - June 1996)  
Dragana Djordjevic (1997 - 1998)  
Nancy Ziroli (1996 - 1999)  
Lea Lim (1997-1999)  
Snehal Patel: (1996-2000)
2. Joe Kut: Department of Psychiatry, Loyola University, medical student conducting studies in Biological Psychiatry Psycho-Immunology (September 1990 - November 1992); Resident Fellow at Rush Presbyterian Hospital conducting studies in Biological Psychiatry (August 1994 - June 1996).
3. Loyola University Medical Student Research Fellows  
John Halpin: (June 1992 - July 1993)  
Tatyana Farietta: (September 1993 - August 1994)
4. First Year Medical Student Summer Researchers:  
Jeannie Wang, Gayle McCloskey and Susan Charboneau (1993)  
Michelle Montpetitte and Gigi Ip (1994)  
Derik West and Imrana Malik (1995)  
Luke Halbur (1996)  
Anil Shah and Sarita Keni, (1997)  
Eve Lubbers (1998)
5. Teach Molecular Biology and Protein Chemistry Workshops for undergraduate students enrolled in the Biochemistry course at Rosary College. Workshops conducted at Hines VA Hospital (1991-1997)
6. Medical Research Associates:  
Rubina Hussain, M.D. (September 1992 - July 1993)  
Arain Javed, M.D. (summer 1994)  
Safewat Eskandar, M.D. (1994-1995)  
Shreyash Pandya, M.D. (1996-1997)
7. Department of Otolaryngology, Loyola University Residents on Research Rotations:  
Ari Taitz, M.D. (July 1994 - February 1995)  
Abhay Vaydia, M.D. (July 1995 - October 1995)

- Mary Totten, M.D. (November 1995 - February 1996)  
 Joe Donzelli, M.D. (March 1996 - June 1996)  
 Ari Taitz, M.D. (July 1996 - October 1997 1996)  
 Thomas Garrity, M.D. (November 1996 - February 1997)  
 Rajiv Pandit, M.D. (July 1996 - March 1997)  
 Landon Riggs, M.D. (March 1997 - June 1997)  
 Kevin Cavanaugh, M.D. (July 1997 - October 1997)  
 Bobby Mukkamali, M.D. (November 1997 - February 1998)  
 Steven Gabel, M.D. (March 1998 - June 1998)  
 Chris Witt, M.D. (July 1998 – October 1998)  
 Sarah Fowler, M.D. (November 1998 – February 1999)  
 Rajiv Pandit, M.D. (March 1999 – June 1999)  
 Brian Wachter, M.D. (July 1999 – October 1999)  
 Christopher Hampton, M.D. (November 1999 – February 2000)  
 John Brockenbrough, M.D. (March 2000 – June 2000)  
 Kevin Hulett, M.D. (July 2000 – October 2000)  
 George Moynihan, M.D. (November 2000 – February 2001)  
 Atul Vaidya, M.D. (March 2001 – June 2001)  
 James Banich, M.D. (July 2001 – October 2001)  
 Rob King, M.D. (November 2001 – February 2002)  
 Curtis Walsh, M.D. (March 2002 – June 2002)  
 Alex Romashko, M.D. (July 2002 – October 2002)
8. Fourth Year Medical Student Research Rotation  
 Sarah Fowler, Sebastian Scobercea, Jim Kalkanis, Greg Winters, Craig Fischhoff (1995)  
 Mike Halburn and Rich Bergstrom (1996)  
 Dan Madziarz (1997)  
 Alison Ford (1998)  
 Anthony Sparano (2001) (received “American Academy of Otolaryngology – Head and Neck Surgery Medical Student Award” for research paper)
9. Postdoctoral Research Associates:  
 Annetee Schmidt-Pak, Ph.D. (1992-1994)  
 George D. Maier, Ph.D. (1992-1996)  
 Raymond Metz, Ph.D. (1995-1998)  
 Margaret Prechel, Ph.D.: (1994-1999)  
 Deanne M.R. Lathers, Ph.D.: (1997-2001)  
 Tamara Wrone-Smith, Ph.D.: (1999-2001)
10. Mentor for students of the Illinois Mathematics and Science Academy:  
 December 1995 - June 1996: Courtenay Diehl and Snigda Vallabhaneni  
 September 1996 - June 1997: Charley Ding and Erin Slone  
 September 1997 - June 1998: Charley Ding and Irene Ma  
 September 1998 - June 1999: Andrea Bonkowski and Adam Rojan
11. Mentor for Nelson Allen, Robert Wood Johnson fellow (Summer 1996).

12. Mentor Student Research Assistants  
Yvonne Lozano: part-time Student Researcher (1992-1994); full-time Research Assistant (1994-1996)  
Kristina Wiers: part-time Student Researcher (1995-1996); full-time Research Assistant (1996-1998)  
Kathleen Bauler: Research Volunteer (1996-1999)  
Julie O'Donnell: Laboratory Research Technician (1998-1999)
13. Summer Student Researchers, Hines VA Hospital  
Sandeep Devata (1993-1996)  
Jeremy Meisinger (1995-1996)  
Summa Devata (1996-1997)  
Janette Holub (1997)  
Kishore Vellody (1995-1998)  
Damien Stankiewicz (1999)  
Alyssa Beckmann (1999)
14. Mentor for students on an NIH-sponsored minority student out-reach program:  
Remy Washington and Fenisha Hubbard (1997).

#### **CURRENT STUDENT RESPONSIBILITIES:**

1. Science Student Fellowship Awardee, Hines VA Hospital:  
Gwen Wera (1998-2003)  
Juan Ortega (2001-2003)  
Beth Kessler (2002-2003)
2. Department of Otolaryngology: Director of Resident Research Program.  
Current resident on research rotation: Alex Romashko, M.D. (March 2002 – 2003)

#### **ADDITIONAL CURRENT RESEARCH/TEACHING RESPONSIBILITIES WITHIN MY LABORATORY**

1. Jeremy Meisinger: Laboratory Assistant (1997-2003)
2. Kristin Kolesiak: Laboratory Assistant (1998-2003)
3. Nicholas Achille: Laboratory Assistant (2000-2003)
4. Eli Gonzales: Student Researcher (2000-2003)
5. Deanne Ridley Lathers, Ph.D.: Mentored on her VA Entry-Level Merit-Review Grant (2001-present)
6. Carol Bier-Laning, M.D.: Mentor on her VA Career Development Award (2001-2003)

#### **EXTRAMURAL INVITED LECTURER (A few representative lectures listed):**

1. Tumor stimulation of myelopoiesis and the resultant appearance of bone marrow-derived immune suppressor cells. 2nd International Meeting of Anticancer Res., Saronis, Greece, October 13, 1988.

2. Lessening of myelopoiesis and the associated bone marrow-derived immune suppressor cells in tumor bearers by interferon- $\gamma$  and tumor necrosis factor- $\alpha$ . 2nd International Meeting of Anticancer Res., Saronis, Greece, October 13, 1988.
3. Mechanisms of immune suppression in tumor-bearing mice. Hokkaido University Cancer Institute, Sapporo Japan, September 10, 1989.
4. Use of cytokine therapy to eliminate immune suppressor cells. Hayashibara Biochemical labs, Okayama, Japan, September 14, 1989.
5. Role of prostaglandin E<sub>2</sub> in stimulating tumor metastasis. Toyama Medical and Pharmaceutical University, Toyama, Japan, September 17, 1989.
6. Myelopoiesis-associated immune suppressor cells in tumor bearers. International Congress of Leukocyte Biology, Crete, Greece, October 14, 1990.
7. Myelopoiesis stimulates metastatic properties of cancer cells. Michigan Cancer Institute, Detroit, MI, June 22, 1991.
8. Flow cytometric analysis for immune suppressive GM-progenitor cells. Department of Biological Physics, Moscow University, Moscow, Russia, September 12, 1991.
9. Regulation of tumor-induced myelopoiesis by PGE<sub>2</sub>. Mid-Winter Meeting of the Prostaglandin Society, Keystone, CO, January 19, 1993.
10. Tumor responsiveness to the metastasis-stimulatory effects of prostaglandin E<sub>2</sub> is restricted by protein phosphatases. 3<sup>rd</sup> International Conference on Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Radiation Injury, Washington, D.C., October 14, 1993.
11. Protein phosphatases-1 and -2A regulate tumor cell migration, invasion, and cytoskeletal organization. 4<sup>th</sup> International Conference on Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Radiation Injury. Hong Kong, October 6, 1995.
12. Role of microglia in Alzheimer's Disease. Procter & Gamble-Miami Valley Center, Cincinnati, OH, March 31, 1996.
13. GM-progenitor cells: Friend or Foe? University of Nebraska Medical Center at Omaha. Pathology Grand Rounds. September 25, 1996.
14. Immune suppressive GM-progenitor cells: Smith-Kline. November 18, 1997.
15. CD34<sup>+</sup> cells: friend or foe? Finch University of Health Sciences / The Chicago Medical School. February 1999.
16. Tumor immunology – from the bench to the clinic. Grand Rounds, Department of Otolaryngology, University of Michigan, Ann Arbor. July 22, 1999.
17. CD34<sup>+</sup> progenitor cells in tumor bearers. Grand Rounds, Department of Gastroenterology, University of Illinois at Chicago, January 17, 2000.
18. How to have it all. Association for Women in Science – Chicago Area Chapter, February 10, 2000
19. CD34<sup>+</sup> progenitor cells in cancer patients. Grand Rounds, Moffitt Cancer Center, Tampa, FL, October 3, 2001.

## INVITED PARTICIPANT IN MEETINGS: (REPRESENTATIVE SAMPLE)

1. Invited to chair session on "Kinases and Phosphatases" at the 3<sup>rd</sup> International Conference on Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Radiation Injury. Washington, D.C., October 14, 1993.
2. Invited to chair session on "Cell Growth" at the 4<sup>rd</sup> International Conference on Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Radiation Injury. Hong Kong, October 4, 1995.
3. Invited to chair session on "Tumor Antigen Presentation, Costimulation, Normal and Abnormal T-cell Activation Minisymposium " at the American Association for Cancer Research Meeting. San Diego, April 14, 1997.
4. Invited to present course entitled "Clinically Relevant Tumor Immunology" at the annual meeting of the American Academy of Otolaryngology-Head and Neck Surgery, September 15, 1998, San Antonio, TX
5. Invited to chair session on "Immunotherapy of Cancer " at the American Association of Immunologists Meeting. Washington D.C., April 17, 1999.
6. Invited panelist for the 5<sup>th</sup> International Conference on Head and Neck Cancer. San Francisco, CA. July 29-August 2, 2000.

## BIBLIOGRAPHY:

### PUBLICATIONS IN PEER-REVIEWED JOURNALS

1. **Ivanoff (Young)**, M.R., and Renshaw, H.W. Weak calf syndrome: serum immunoglobulin concentrations in precolostral calves. *Am. J. Vet. Res.* 36:1129-1134, 1975.
2. **Young**, M.R. and McIvor, K.L. Enhancement of thymus cell function by macrophage culture supernatants. *J. Reticuloendothel. Soc.* 27:39-47, 1980.
3. **Young**, M.R., Cheung, H.T. and Sundharadas, G. Selective inhibition of tumor cell migration by culture supernatants derived from normal and lipopolysaccharide activated macrophages. *J. Reticuloendothel. Soc.* 27:143-150, 1980.
4. **Young**, M.R., Sundharadas, G., Cantarow, W.D. and Kumar, P.R. Purification and functional characterization of a low molecular weight immune modulating factor produced by Lewis lung carcinoma. *Int. J. Cancer* 30:517-524, 1982.
5. **Young**, M.R. and Henderson, S. Enhancement in immunity of tumor bearing mice by immunization against prostaglandin E<sub>2</sub>. *Immunol. Comm.* 11:345-356, 1982.
6. **Young**, M.R. and Dizer, M. Enhancement of immune function and tumor growth inhibition by antibodies against prostaglandin E<sub>2</sub>. *Immunol. Comm.* 12:11-23, 1983.
7. **Young**, M.R. and Knies, S. Prostaglandin E production by Lewis lung carcinoma: Mechanism for tumor establishment *in vivo*. *J. Natl. Cancer Inst.* 72:919-922, 1984.

8. **Young, M.R.** and Simmermaker, J. Prostaglandin E<sub>2</sub> regulates production of tumoristatic factors by macrophage-like P388D1 cells. *J. Natl. Cancer Inst.* 73:959-962, 1984.
9. Mahan, M., Meunier, J., Newby, M. and **Young, M.R.** Prostaglandin E<sub>2</sub> production by EL4 leukemia cells: Mechanism for tumor dissemination. *J. Natl. Cancer Inst.* 74:191-195, 1985.
10. **Young, M.R.**, Meunier, J. and Newby, M. Relationships between morphology, dissemination, migration and prostaglandin E<sub>2</sub> secretion by cloned variants of Lewis lung carcinoma. *Cancer Res.* 45:3918-3923, 1985.
11. **Young, M.R.** and Newby, M. Enhancement of tumor cell migration by prostaglandin E<sub>2</sub> produced by macrophages. *Cancer Res.* 46:160-164, 1986.
12. **Young, M.R.**, Wheeler, E. and Newby, M. Macrophage-mediated suppression of natural killer cell activity in mice bearing Lewis lung carcinoma. *J. Natl. Cancer Inst.* 76:745-750, 1986.
13. Nikcevich, D.A., **Young, M.R.**, Ellis, N.K., Newby, M. and Wepsic, H.T. Stimulation of hematopoiesis in untreated and cyclophosphamide treated mice by the inhibition of prostaglandin synthesis. *J. Immunopharmacol.* 8:299-313, 1986.
14. **Young, M.R.** and Hoover, C.S. Inhibition of the spleen cell cytotoxic capacity toward tumor by the elevated prostaglandin E<sub>2</sub> levels in mice bearing Lewis lung carcinoma. *J. Natl. Cancer Inst.* 77:425-429, 1986.
15. **Young, M.R.** and Newby, M. Differential induction of suppressor macrophages by cloned Lewis lung carcinoma variants. *J. Natl. Cancer Inst.* 77:1255-1260, 1986.
16. Ellis, N.K., **Young, M.R.**, Nikcevich, D.A., Newby, M. and Wepsic, H.T. Stimulation of prostaglandin dependent macrophage suppressor cells by the subcutaneous injection of polyunsaturated fatty acids. *Cell. Immunol.* 102:251-260, 1986.
17. **Young, M.R.**, Newby, M. and Wepsic, H.T. Hematopoiesis and suppressor bone marrow cells in mice bearing large metastatic Lewis lung carcinoma tumors. *Cancer Res.* 47:100-105, 1987.
18. **Young, M.R.**, Duffie, G.P. and Newby, M. Adhesiveness and morphology of Lewis lung carcinoma variants influence their sensitivity to natural killer cytotoxicity and their metastatic capacity. *Invasion Met.* 7:96-108, 1987.
19. **Young, M.R.**, Ellis, N.K., Young, M.E. and Wepsic, H.T. Stimulation of hematopoiesis and bone marrow suppressor cells by the subcutaneous injection of linoleic acid. *Cell. Immunol.* 107:238-248, 1987.
20. **Young, M.R.**, Young, M.E. and Wepsic, H.T. The effect of prostaglandin E<sub>2</sub>-producing nonmetastatic LLC cells on the migration of prostaglandin E<sub>2</sub>-responsive metastatic LLC cells. *Cancer Res.* 47:3679-3683, 1987.
21. **Young, M.R.**, Endicott, R.A., Duffie, G.P. and Wepsic, H.T. Suppressor alveolar macrophages in mice bearing Lewis lung carcinoma tumors. *J. Leuko. Biol.* 42:682-688, 1987.

22. Nikcevich, D.A., Duffie, G.P., **Young**, M.R., Ellis, N.K., Kaufman, G.E. and Wepsic, H.T. Stimulation of suppressor cells in the bone marrow and spleens of high dose cyclophosphamide treated C57Bl/6 mice. *Cell. Immunol.* *109*:349-359, 1987.
23. **Young**, M.R., Young M.E. and Wepsic, H.T. The effect of recombinant interferon- $\gamma$  on the hematopoietic and immunological parameters of mice bearing metastatic Lewis lung carcinoma tumors. *Exp. Hematol.* *16*:295-301, 1988.
24. **Young**, M.R., Young, M.E. and Kim, K. Regulation of tumor-induced myelopoiesis and the associated immune suppressor cells in mice bearing metastatic Lewis lung carcinomas by prostaglandin E<sub>2</sub>. *Cancer Res.* *48*:6826-6831, 1988.
25. Duffie, G.P., Romanelli, R.R., Ellis, N.K., **Young**, M.R. and Wepsic, H.T. The effect of E series prostaglandins on blastogenic responses *in vitro* and graft vs. host responses *in vivo*. *Immunopharmacol. Immunotoxicol.*, *10*:597-615, 1988
26. Mahan, M.P. and **Young**, M.R. Immune parameters of exercise-stressed and exercise-conditioned rats. *J. Appl. Physiol.* *66*:282-287, 1989.
27. **Young**, M.R., Aquino, S. and Young, M.E. Differential induction of hematopoiesis and immune suppressor cells in the bone marrow versus in the spleen by Lewis lung carcinoma variants. *J. Leuko. Biol.* *45*:262-273, 1989.
28. **Young**, M.R., Young, M.E. Effects of fish oil diets on prostaglandin-dependent and myelopoiesis-associated immune suppressor mechanisms of mice bearing metastatic Lewis lung carcinoma tumors. *Cancer Res.* *49*:1931-1936, 1989.
29. Ellis, N.K., Duffie, G.P., **Young**, M.R., Wepsic, H.T. The effects of 16, 16-dimethyl PGE<sub>2</sub> and phosphodiesterase inhibitors on Con-A blastogenic responses and NK cytotoxic activity of mouse spleen cells. *J. Leuko. Biol.*, *47*:371-377, 1990.
30. **Young**, M.R.I., Duffie, G.P., Lozano, Y., Young, M.E., Wright, M.A. Association of a functional prostaglandin E<sub>2</sub>- (PGE<sub>2</sub>) protein kinase A coupling with responsiveness of metastatic Lewis lung carcinoma (LLC) variants to PGE<sub>2</sub> and to PGE<sub>2</sub>-producing nonmetastatic LLC variants. *Cancer Res.*, *50*:2973-2978, 1990.
31. **Young**, M.R.I., Young, M.E., Wright, M.A. Myelopoiesis-associated suppressor cell activity in mice with Lewis lung carcinoma tumors: interferon- $\gamma$  plus tumor necrosis factor- $\alpha$  synergistically reduce suppressor cell activity. *Int. J. Cancer*, *46*:245-250, 1990.
32. **Young**, M.R.I. Modulation of eicosanoid biosynthesis and inhibition of substrate availability for phospholipase A<sub>2</sub> by a modified hexose sugar, amiprilose hydrochloride. *Prostaglandins*, *40*:35-49, 1990.
33. **Young**, M.R.I., Young, M.E., Wright, M.A. Stimulation of immune suppressive bone marrow cells by colony stimulating factors. *Exp. Hematol.*, *18*:806-811, 1990.
34. Duffie, G.P. and **Young**, M.R.I. Tumoricidal activity of alveolar and peritoneal macrophages of C57Bl/6 mice bearing metastatic or nonmetastatic variants of Lewis lung carcinoma. *J. Leuko. Biol.*, *49*:8-14, 1991.
35. Rahman, M.A., Sauter, D.C., **Young**, M.R. Effects of dietary fish oil on the induction of experimental membranous nephropathy in the rat. *Lab. Invest.*, *64*:371-376, 1991.

36. **Young, M.R.I., Okada, F., Tada, M, Hosokawa, M., Kobayashi, H.** Association of increased tumor cell responsiveness to prostaglandin E<sub>2</sub> with more aggressive tumor behavior. *Invasion Met.*, *11*:48-57, 1991.
37. **Young, M.R.I., Wright, M.A., Young, M.E.:** Antibodies to colony-stimulating factors block Lewis lung carcinoma cell-stimulation of immune suppressive bone marrow cells. *Cancer Immunol. Immunother.*, *33*:146-152, 1991.
38. **Azad, N., Jurgens, J., Young, M.R., Reda, D., Duffner, L., Kirsteins, L., Emanuele, N.V., Lawrence, A.M.** Presence of luteinizing hormone-releasing hormone in rat thymus. *Prog. NeuroEndocrinImmunol.*, *4*:113-120, 1991.
39. **Young, M.R.I., Young, M.E., Lozano, Y., Coogan, M., Bagash, J.M.** Regulation of protein kinase A activation and prostaglandin E<sub>2</sub>-stimulated migration of Lewis lung carcinoma clones. *Int. J. Cancer*, *49*:150-155, 1991.
40. **Young, M.R.I, Lozano, Y., Coogan, M., Wright, M.A., Young, M.E., Bagash, J.M.** Stimulation of the metastatic properties of Lewis lung carcinoma cells by autologous granulocyte-macrophage colony-stimulating factor. *Int. J. Cancer*, *50*:628-634, 1992.
41. **Young, M.R.I., Wright, M.A., Coogan, M., Young, M.E., Bagash, J.** Tumor-derived cytokines induce bone marrow suppressor cells which mediate immune suppression through transforming growth factor  $\beta$ . *Cancer Immunol. Immunother.*, *35*:14-18, 1992.
42. **Goto, M., Yoshioka, T., Young, R., Gottschalk, M.E., Anderson, C.L., Zeller, W.P.** Early endotoxin tolerance in suckling rats. *Res. Comm. Chem. Pathol. Pharmacol.*, *76*:249-252, 1992.
43. **Kut, J.L., Young, M.R.I., Crayton, J.W., Wright, M.A., Young, M.E.** Regulation of murine T-lymphocyte function by spleen cell-derived and exogenous serotonin. *Immunopharmacol. Immunotoxicol.*, *14*:783-796, 1992.
44. **Young, M.R.I., Wright, M.A.** Myelopoiesis-associated immune suppressor cells in mice bearing metastatic Lewis lung carcinoma tumors: *In vivo* use of interferon- $\gamma$  plus tumor necrosis factor- $\alpha$  to synergistically reduce immune suppressor and tumor growth-promoting activities of bone marrow cells, and to diminish tumor recurrence and metastasis. *Cancer Research*, *52*:6335-6340, 1992
45. **Young, M.R.I., Young, M.E, Lozano, Y., Bagash, J.M.** Activation of protein kinase A increases the *in vitro* invasion, migration and adherence to reconstituted basement membrane by Lewis lung carcinoma tumor cells. *Invasion Met.*, *12*:253-263, 1992.
46. **Young, M.R.I., Lozano, Y., Djordjevic, A., Devata, S., Matthews, J., Young, M.E., Wright, M.A.** Granulocyte-macrophage colony-stimulating factor stimulates the metastatic properties of Lewis lung carcinoma cells through a protein kinase A signal transduction pathway. *Int. J. Cancer*, *53*: 667-671, 1993.
47. **Young, M.R.I., Lozano, Y., Dzorjevic, A., Maier, D.** Protein phosphatases limit tumor motility. *Int. J. Cancer*, *54*: 1036-1041, 1993.
48. **Yoshioka, T., Goto, M., Kodama, M. Gottschalk, M.E., Anderson, C.L., Young, M.R.I., Zeller, W.P.** J5 prevents endotoxin shock in suckling rats. *Res. Comm. Chem. Pathol. Pharmacol.* *80*: 367-370, 1993.

49. **Young**, M.R., Kut, J.L., Coogan, M.P., Wright, M.A., Young, M.E., Matthews, J. Stimulation of splenic T-lymphocyte function by endogenous serotonin and by low dose exogenous serotonin. *Immunology*, 80: 395-400, 1993.
50. **Young**, M.R.I., Halpin, J., Wang, J., Wright, M.A., Matthews, J., Schmidt Pak, A.  $1\alpha,25$ -dihydroxyvitamin D<sub>3</sub> plus interferon- $\gamma$  block lung tumor production of granulocyte-macrophage colony-stimulating factor and induction of immune suppressor cells. *Cancer Res.*, 53: 6006-6010, 1993.
51. **Young**, M.R.I., Halpin, J., Hussain, R., Lozano, Y., Djordjevic, A., Devata, S., Matthews, J., Wright, M.A. Inhibition of tumor production of granulocyte-macrophage colony-stimulating factor by  $1\alpha,25$ -dihydroxyvitamin D<sub>3</sub> reduces tumor motility and metastasis. *Invasion Met.*, 13: 169-177, 1993.
52. **Young**, M.R.I., McCloskey, G., Wright, M.A., Schmidt Pak, A. Increasing infiltration and activation of CD8<sup>+</sup> tumor-infiltrating lymphocytes after eliminating immune suppressive granulocyte-macrophage progenitor cells with low doses of interferon- $\gamma$  plus tumor necrosis factor- $\alpha$ . *Cancer Immunol. Immunother.*, 38:9-15, 1994.
53. **Young**, M.R.I., Charboneau, S., Lozano, Y., Djordjevic, A., Young, M.E. Activation of the protein kinase A signal transduction pathway by granulocyte-macrophage colony-stimulating factor or by genetic manipulation reduces cytoskeletal organization in Lewis lung carcinoma variants. *Int. J. Cancer*, 54:446-451, 1994.
54. Goto, M., Yoshioka, T., Ravindranath, T., Battelino, T., **Young**, R.I., Zeller, W.P. LPS injected into the pregnant rat late in gestation does not induce fetal endotoxemia. *Res. Commun. Mol. Pathol. Pharmacol.*, 85: 109-112, 1994.
55. Schmidt-Pak, A., Wright, M.A., Matthews, J.P., Collins, S.L., Petruzzelli, G., **Young**, M.R.I. Mechanisms of immune suppression in patients with head and neck cancer: Presence of immune suppressive CD34<sup>+</sup> cells within cancers that secrete granulocyte-macrophage colony-stimulating factor. *Clin. Cancer Res.*, 1:95-103, 1995.
56. **Young**, M.R.I., Matthews, J.P. Serotonin regulation of T-cell subpopulations and of macrophage accessory function. *Immunology*, 84:148-152, 1995.
57. **Young**, M.R.I., Matthews, J.P., Kanabrocki, R.B., Sothorn, B., Roitman-Johnson, B., Scheving, L.E. Circadian rhythmometry of serum interleukin-2, interleukin-10, tumor necrosis factor- $\alpha$  and granulocyte-macrophage colony-stimulating factor in adult men. *Chronobiology Int.*, 12: 19-27, 1995.
58. Maier, G.D., Wright, M.A., Lozano, Y., Djordjevic, A., Matthews, J.P., **Young**, M.R.I. Regulation of cytoskeletal organization in tumor cells by protein phosphatases-1 and -2A. *Int. J. Cancer*, 61: 51-54, 1995.
59. **Young**, M.R.I., Farietta, T., Crayton, J.W. Brain production of nitric oxide and transforming growth factor- $\alpha$ . *Mech. Ageing Dev.*, 79:115-126, 1995.
60. Schmidt-Pak, A., Ip, G., Wright, M.A., **Young**, M.R.I. Treating tumor-bearing mice with low dose interferon- $\gamma$  plus tumor necrosis factor- $\alpha$  to diminish immune suppressive granulocyte-macrophage progenitor cells increases responsiveness to IL-2 immunotherapy. *Cancer Res.*, 55: 885-890, 1995.

61. **Young, M.R.I.,** Montpetit, M., Lozano, Y., Djordjevic, A., Devata, S., Matthews, J.P., Yedavalli, S., Cheijfec, G. Lewis lung carcinoma transfectants that either overexpress or have defective protein kinase A activity have a respective high or low capacity to invade and metastasize *in vivo*. *Int. J. Cancer*, *64*:104-109, 1995.
62. Prechel, M.M., Lozano, Y., Wright, M.A., Ihm, J., **Young, M.R.I.** Ineffective immune enhancement by IL-12 in tumor-bearing mice whose immune depression is mediated by suppressive granulocyte-macrophage progenitor cells. *Cancer Lett.*, *92*: 235-22, 1995.
63. Taitz, A., Petruzzelli, G., Pak, A.S., Wright, M.A., Matthews, J.P., Raslan, W.F., Lozano, Y., **Young, M.R.I.** Immune parameters of mice bearing human head and neck cancer. *Cancer Immunol. Immunother.*, *40*:283-291, 1995.
64. Sothorn, R.B., Roitman-Johnson, B., Kanabrocki, E.L., Yager, J.G., Roodell, M.M., **Young, M.R.**, Nemchausky, B.M., Scheving, L.E. Circadian characteristics of circulating interleukin-6 in men. *J. Allergy Clin. Immunol.*, *95*: 1029-1035, 1995.
65. **Young, M.R.I.,** Ihm, J., Lozano, Y., Wright, M.A., Prechel, M.M. Treating tumor-bearing mice with vitamin D<sub>3</sub> diminishes tumor-induced myelopoiesis and associated immune suppression, and reduces tumor metastasis and recurrence. *Cancer Immunol. Immunother.*, *41*:37-45, 1995.
66. Sothorn, R.B., Roitman-Johnson, B., Kanabrocki, E.L., Yager, J.G., Fuerstenberg, R.K., Weatherbee, J.A., **Young, M.R.I.,** Nemchausky, B.M., Scheving, L.E. Circadian characteristics of interleukin-6 in blood and urine of clinically healthy men. *In vivo*, *9*:331-340, 1995.
67. Taitz, A, Petruzzelli, G.J., Lozano, Y., Shankar, R., **Young, M.R.I.** Bi-directional stimulation of adherence to extracellular matrix components by human head and neck squamous carcinoma cells and endothelial cells. *Cancer Lett.*, *96*:253-260, 1995.
68. Lozano, Y., Taitz, A., Petruzzelli, G.J., Djordjevic, A., Yedavalli, S., **Young, M.R.I.** Prostaglandin E<sub>2</sub>-protein kinase A signaling and protein phosphatases-1 and -2A regulate human head and neck squamous cell carcinoma motility, adherence to extracellular matrix components, and cytoskeletal organization. *Prostaglandins*, *51*: 35-48, 1996.
69. **Young, M.R.I.,** Wright, M.A., Matthews, J.P., Malik, I., Prechel, M. Suppression of T-cell proliferation by tumor-induced granulocyte-macrophage progenitor cells producing transforming growth factor- $\alpha$  and nitric oxide. *J. Immunol.*, *156*:1916-1922, 1996.
70. Maier, G.D., Vellody, K., Meisinger, J., Djordjevic, A., Lozano, Y., **Young, M.R.I.** Protein kinase A regulates Lewis lung carcinoma metastasis and adherence to extracellular matrix components. *Clin. Exp. Metastasis*, *14*:314-322, 1996.
71. **Young, M.R.I.,** Lozano, Y., Ihm, J., Wright, M.A., Prechel, M.M. Vitamin D<sub>3</sub> treatment of tumor bearers can stimulate immune competence and reduce tumor growth when treatment coincides with a heightened presence of natural suppressor cells. *Cancer Lett.*, *104*:153-161, 1996.

72. Prechel, M.M., Lozano, Y., Wright, M.A., Ihm, J., **Young**, M.R.I. Immune modulation by interleukin-12 in tumor-bearing mice receiving vitamin D<sub>3</sub> treatments to block induction of immune suppressor cells. *Cancer Immunol. Immunother.*, *42*:213-220, 1996.
73. **Young**, M.R.I., Wright, M.A., Lozano, Y., Matthews, J.P., Benefield, J., Prechel, M.M. Mechanisms of immune suppression in patients with head and neck cancer: influence on the immune infiltrate of the cancer. *Int. J. Cancer*, *67*:333-338, 1996.
74. Benefield, J., Petruzzelli, G.J., Fowler, S., Taitz, A., **Young**, M.R.I. Regulation of the steps of angiogenesis by human head and neck squamous cell carcinomas. *Inv. Met.*, *16*:291-301, 1996.
75. Metz, R., Vellody, K., Patel, S., Bergstrom, R., Meisinger, J., Jackson, J., Wright, M.A., Lozano, Y., **Young**, M.R.I. Vitamin D<sub>3</sub> and ceramide reduce the invasion of tumor cells through extracellular matrix components by elevating protein phosphatase-2A. *Inv. Met.*, *16*:280-290, 1996.
76. **Young**, M.R.I., Lozano, Y. Inhibition of tumor invasiveness by 1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> coupled to an increase in cytoskeletal organization and decline in protein kinase A activity. *Clin. Exp. Met.*, *15*:102-110, 1997.
77. **Young**, M.R.I., Wright, M.A., Lozano, Y., Prechel, M.M., Benefield, J., Leonetti, J.P., Collins, S.L., Petruzzelli, G.J. Increased recurrence and metastasis in patients whose primary head and neck squamous cell carcinomas secreted granulocyte-macrophage colony-stimulating factor and contained CD34<sup>+</sup> natural suppressor cells. *Int. J. Cancer*, *74*:69-74, 1997.
78. Meisinger, J., Patel, S., Vellody, K., Bergstrom, R., Benefield, J., Lozano, Y., **Young**, M.R.I. Protein phosphatase-2A association with microtubules and its role in restricting the invasiveness of human head and neck squamous cell carcinoma cells. *Cancer Lett.*, *111*:87-95, 1997.
79. Prechel, M.M., Halbur, L., Vaidya, A.M., Devata, S., **Young**, M.R.I. Increased interleukin-6 production by cerebral cortical tissue of adult versus young mice. *Mech. Ageing Dev.*, *92*:185-194, 1997.
80. Wiers, K., Lozano, Y., Messingham, K.A.N., Metz, R., **Young**, M.R.I. 1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> differentially regulates activation of normal T-cells versus T-cells of tumor bearers through protein phosphatase-2A. *Cancer Immunol. Immunother.*, *44*:97-102, 1997.
81. Vaidya, A.M., Chow, J.M., Stankiewicz, J.A., Mathews, H.L., **Young**, M.R.I. Correlation of middle meatal to maxillary sinus culture. *Am. J. Rhinology*, *11*:139-143 1997.
82. **Young**, M.R.I., Wright, M.A., Pandit, R. Myeloid differentiation treatment to diminish the presence of immune suppressive CD34<sup>+</sup> cells within human head and neck squamous cell carcinomas. *J. Immunol.* *159*:990-996, 1997.
83. NcNulty, J.A., Prechel, M.M., **Young**, M.R., Fox, L.M. Pinealocyte ultrastructure in mutant mice that lack sympathetic innervation to the pineal gland. *J. Submicroscop. Cytol. Path.*, *29*:305-311, 1997.

84. Goto, M., Yoshioka, T., **Young**, M.R.I., Battelino, T., Anderson, C.L., Zeller, W.P. A sublethal dose of LPS to pregnant rats induces TNF- $\alpha$  tolerance in their 0-day old offspring. *Am. Physiol. Soc.*, :273:R1158-R1162, 1997.
85. Ravindranath, T., Yoshioka, Y., Goto, M., Issac, R., Goldman, G., **Young**, M.R.I., Zeller, W.P. Endotoxin translocation following enteral refeeding in children. *Clin. Pediatrics*, 36:523-528, 1997.
86. Petruzzelli, G.J., Benefield, J., Taitz, A..D., Fowler, S., Kalkanis, J., Scobercea, S., West, D., **Young**, M.R.I. Heparin binding growth factor(s) derived from head and neck squamous cell carcinomas induce endothelial cell proliferation. *Head and Neck*, 19:576-582, 1997.
87. Jackson, J., Meisinger, J., Patel, S., Lim, Z.C., Vellody, K., Metz, R., **Young**, M.R.I. Protein phosphatase-2A associates with the cytoskeleton to maintain cell spreading and reduced motility of nonmetastatic Lewis lung carcinoma cells; the loss of this regulatory control in metastatic cells. *Inv. Met.*, 17:199-209, 1997.
88. Benefield, J., Meisinger, J., Petruzzelli, G.J., **Young**, M.R.I. Endothelial cell response to human head and neck squamous cell carcinoma cells involves downregulation of protein phosphatases-1/2A, cytoskeletal depolymerization and increased motility. *Invasion Met.*, 17:210-220, 1997
89. Garrity, T., Pandit, R., Wright, M.A., Benefield, J., Keni, S., **Young**, M.R.I. Increased presence of CD34<sup>+</sup> cells in the peripheral blood of head and neck cancer patients and their differentiation into dendritic cells. *Int. J. Cancer*, 73: 663-669, 1997.
90. **Young**, M.R.I. Protein phosphatases-1 and -2A regulate- tumor cell migration, invasion, and cytoskeletal organization. *Adv. Exp. Med. Biol.*, 407:311-318, 1997.
91. Donzelli, J., Leonetti, J.P., Bergstom, R.S., Wurster, R.D., **Young**, M.R.I. Thermoprotective mechanisms of irrigation during bipolar cautery. *Otolaryngol. - Head and Neck Surg.*, 119:153-158, 1998.
92. Wiers, K., Wright, M.A., Vellody, K., **Young**, M.R.I. Failure of tumor-reactive lymph node cells to kill tumor in the presence of immune suppressive CD34<sup>+</sup> cells can be overcome with vitamin D<sub>3</sub> treatment to diminish CD34<sup>+</sup> cell levels. *Clin. Exp. Met.*, 16: 275-282,1998.
93. Wright, M.A., Wiers, K., Vellody, K., Djordjevic, D., **Young**, M.R.I. Stimulation of immune suppressive CD34<sup>+</sup> cells from normal bone marrow by Lewis lung carcinoma tumors. *Cancer Immunol. Immunother.*, 46: 253-260, 1998.
94. Riggs, L.C., Shofner, W.P., Shah, A.R., Young, M.R.I., Hain, T.C., Matz, G.J. Ototoxicity resulting from combined administration of metronidazole and gentamicin. *Am. J. Otolaryngology*, 2: 430-434, 1999,
95. Gabel, S., Benefield, J., Mesinger, J., Petruzzelli, G.J., **Young**, M.R.I. Protein phosphatases-1 and -2A maintain endothelial cells in a resting state, limiting the motility that is needed for the morphogenic process of angiogenesis. *Otolaryngology - Head and Neck Surgery*, 121: 463-468, 1999.

96. Lathers, D.M.R., Wright, M.A., Wiers, K.M., **Young**, M.R.I. Dendritic cell differentiation pathways of CD34<sup>+</sup> cells from the peripheral blood of head and neck cancer patients. *J. Leukocyte Biol.*, 65: 623-628, 1999.
97. Young, M.R.I., Wright, M.A., Lathers, D.M.R., Messingham, K.A. Increased resistance to apoptosis by bone marrow CD34<sup>+</sup> progenitor cells from tumor-bearing mice. *Int. J. Cancer*, 802: 609-615, 1999.
98. **Young**, M.R.I., Wright, M.A., Vellody, K., Lathers, D.M.R. Skewed differentiation of bone marrow CD34<sup>+</sup> cells of tumor bearers from dendritic toward monocytic cells, and the reduction of differentiation toward dendritic cells by 1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>. *Int. J. Immunopharmacol.*, 21: 675-688, 1999.
99. Lathers, D.M.R., Lubbers, E., Beal, N.M., Wright, M.A., **Young**, M.R.I. Cultures derived from peripheral blood CD34<sup>+</sup> progenitor cells of head and neck cancer patients and from cord blood are functionally different. *Human Immunol.*, 60: 1207-1215, 1999.
100. **Young**, M.R.I., Kolesiak, K., Wright, M.A., Gabrilovich, D.I. Chemoattraction of femoral CD34<sup>+</sup> progenitor cells by tumor-derived vascular endothelial cell growth factor. *Clin. Exp. Met.*, 17: 881-888, 1999.
101. Wiers, K.M., Wright, M.A., Lathers, D.M.R., **Young**, M.R.I. Vitamin D<sub>3</sub> treatment to diminish the levels of immune suppressive CD34<sup>+</sup> cells increases the effectiveness of adoptive immunotherapy. *J. Immunother.*, 23: 115-124, 2000.
102. Donzelli, J., Leonetti, J.P., Wurster, R.D., Lee, J.M., **Young**, M.R.I. Neuroprotection when irrigation is included during bipolar cautery. *Arch. Otolaryngol.-Head and Neck Surg.*, 126: 149-153, 2000.
103. Prechel, M.M., Ding, C., Washington, R.L., Kolodziej, M.S., **Young**, M.R.I. *In vivo* indomethacin treatment causes microglial activation in adult mice. *Neurochem. Res.*, 25:357-362, 2000.
104. Pandit, R., Garrity, T., Petruzzelli, G.J., Collins, S.L., Bastian, R.W., **Young**, M.R.I. CD34<sup>+</sup> immune suppressor cells in the blood of head and neck cancer patients. *Annals Otolaryngol., Rhinol. Laryngol.*, in 109:749-754, 2000.
105. Witt, C.J., Gabel, S.P., Meisinger, J., Werra, G., Liu, S.W., **Young**, M.R.I. Inter-relationship between protein phosphatase-2A and the cytoskeletal architecture during the endothelial cell response to soluble products produced by human head and neck cancer. *Otolaryngol – Head Neck Surg.*, 122:721-727, 2000.
106. **Young**, M.R.I., Petruzzelli, G.J., Kolesiak, K., Lathers, D.R., Lingen, D.I., Gabrilovich, D.I. Human squamous cell carcinomas of the head and neck chemoattract immune suppressive CD34<sup>+</sup> progenitor cells. *Human Immunol*, 62: 332-341, 2001.
107. Kanabrocki, E.L., Hermida, R.C., Wright, M., **Young**, M.R.I., Bremner, F.W., Third, J.L.H.C., Ryan, M.D., Ayala, D.E., Johnson, M., Nemchausky, B.A., Shirazi, P., Scheving, L.E., Olwin, J.H. Circadian variation of serum leptin in healthy and diabetic men. *Chronobiol. Int.*, 18: 273-283, 2001.

108. Fowler, S.S., Leonetti, J.P., Banich, J.C., Lee, J.M., Wurster, R., **Young**, M.R.I. Duration of neuronal stretch correlates with functional loss. *Otolaryngol – Head Neck Surg.*, 124: 641-644, 2001.
109. **Young**, M.R.I., Liu, S.W., Meisinger, J. Differences in association of the serine/threonine protein phosphatase PP-2A with microtubules of metastatic and nonmetastatic tumor cells. *Clin. Exp. Met.*, 18: 407-413, 2001.
110. **Young**, M.R.I., Kolesiak, K., Achille, N.J., Meisinger, J., Gonzalez, E., Liu, S.W., Wrone-Smith, T., Lathers, D.M.R. Impact of aging on immune modulation by tumor. *Cancer Immunol. Immunother.*, 50: 315-320, 2001.
111. Lathers, D.M.R., Achille, N., Kolesiak, K., Hulett, K., Sparano, A., **Young**, M.R.I. Increased levels of immune inhibitory CD34<sup>+</sup> progenitor cells in the peripheral blood of patients with node positive head and neck cancer and the ability of the CD34<sup>+</sup> cells to differentiate into antigen presenting dendritic cells. *Otolaryngology – Head Neck Surg.*, 125: 205-212, 2001.
112. Lathers, D.M.R., Clark, J.I., Achille, N.J., **Young**, M.R.I. Phase 1B study of 25-hydroxyvitamin D<sub>3</sub> treatment to diminish suppressor cells in head and neck cancer patients. *Human Immunol.*, 62: 1282-1293, 2001.
113. Shafer, L.L., McNulty, J.A., **Young**, M.R.I. Assessment of metalonin's ability to regulate cytokine production by macrophage and microglia cell types. *J. Neuroimmunol.*, 120: 84-93, 2001.
114. Jackson, J.L., **Young**, M.R.I. Protein phosphatase-2A modulates the serine and tyrosine phosphorylation of paxillin in Lewis Lung Carcinoma tumor variants. *Clin. Exp. Metastasis*, 19: 409-415, 2002.
115. **Young**, M.R.I., Kolesiak, K., Meisinger, J. Protein phosphatase-2A regulates endothelial cell motility and both the phosphorylation as well as stability of focal adhesion complexes. *Int. J. Cancer*, 100: 276-282, 2002.
116. Wachter, B.G., Leonetti, J.P., Lee, J.M., Wurster, R.D., **Young**, M.R.I. Silver nitrate injury in the rat sciatic nerve: a model of facial nerve injury. *Otolaryngol. – Head Neck Surg.*, 127: 48-54, 2002.
117. Banich, J.C., Kolesiak, K., **Young**, M.R.I. Chemoattraction of CD34<sup>+</sup> progenitor cells and dendritic cells to the site of tumor excision as the first step of an immunotherapeutic approach to target residual tumor cells. *J. Immunother.*, 26: 31-40, 2003.
118. **Young**, M.R.I., Liu, S.W., Meisinger, J. Protein phosphatase-2A restricts migration of Lewis lung carcinoma cells by modulating the phosphorylation of focal adhesion proteins. *Int. J. Cancer*, 103: 38-44, 2003.

119. Kanabrocki, E., Wright, M., Hermida, R.C., **Young**, RMI, Bremner, F.W., Third, JLHC, Ryan, M.D., Johnson, M., Nemchausky, B.A., Shirazi, P., Scheving, L.E., Olwin, J.H. Circadian rhythm in serum leptin. *Chrobiol. Int.*, in press, 2003.
120. Shafer, L.L., McNulty, J.A., **Young**, M.R.I. Brain derived soluble factors differentially regulate BV2 microglia and peripheral macrophage immune function. *NeuroImmunoModulation*, 10: 283-294, 2003.
121. Shafer, L.L., McNulty, J.A., **Young**, M.R.I. Brain activation of monocytes-lineage cells: involvement of interleukin (IL)-6. *NeuroImmunoModulation*, 10: 295-304, 2003.
122. Brockenbrough, J.M., Marzo, S., Wurster, R., **Young**, M.R.I. Bone wax prevents nystagmus following labyrinthine fenestration in guinea pigs. *Otolaryngol. – Head Neck Surg.*, 128: 726-731, 2003.
123. Jackson, J.L., Young, M.R.I. Protein phosphatase-2A regulates protein tyrosine phosphatase activity in Lewis lung carcinoma tumor variants. *Clin. Exp. Metastasis*, 20:357-364, 2003.
124. Lathers, D.M.R., Achille, N.J., **Young**, M.R.I. Incomplete Th2 skewing of cytokines in plasma of patients with squamous cell carcinoma of the head and neck. *Human Immunol.*, 64:1160-1166, 2003.
125. **Young**, M.R.I., Lathers, D.M.R. Increased aberrance of cytokine expression in plasma of patients with more advanced squamous cell carcinoma of the head and neck. *Cytokine*, 25:220-228, 2003.
126. **Young**, M.R.I. Tumor skewing of CD34<sup>+</sup> progenitor cell differentiation into endothelial cells. *Int. J. Cancer*, 109:516-524, 2004.
127. Lathers, D.M.R., Clark, J.I., Achille, N.J., **Young**, M.R.I. Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D<sub>3</sub>. *Cancer Immunol. Immunother.* 53: 422-430, 2004.
128. Sparano, A., Lathers, D.M.R., Achille, N.J., Petruzzelli, G.J., **Young**, M.R.I. Modulation of Th1 and Th2 cytokine profiles and their association with advanced head and neck squamous cell carcinoma. *Otolaryngol.-Head Neck Surg.*, in press, 2004.
129. Young, M.R.I. Tumor-derived prostaglandin E<sub>2</sub> and transforming growth factor- $\beta$  stimulate endothelial cell motility through inhibition of protein phosphatase-2A and involvement of PTEN and phosphatidylinositide 3-kinase. *Angiogenesis*, in press, 2004.
130. Romashko A.A., **Young**, M.R.I. Protein phosphatase-2A maintains focal adhesion complexes in keratinocytes and the loss of this regulation in squamous cell carcinomas. *Clin. Exp. Metastasis*, in press, 2004.

#### **CHAPTERS OF BOOKS AND INVITED PAPERS IN PROCEEDINGS**

1. **Young, M.R.** and Newby, M. Differential induction of macrophage prostaglandin E<sub>2</sub> secretion and suppressor activity by Lewis lung carcinoma variants. *In: Prostaglandins and Cancer*, E. Garaci, R. Paoletti and M.G. Santoro (eds.), Springer-Verlag, Berlin Heidelberg. pp. 273-276, 1987.
2. **Young, M.R.** and Wepsic, H.T. Polyunsaturated fat-induced immune suppression: involvement of prostaglandin-producing suppressor cells. *In: Carcinogenesis and Dietary Fat*, S.Abraham (ed.), Martinus Nijhoff,- Boston. pp. 305-319, 1989.
3. **Young, M.R.I.**, Lozano, Y., Djordjevic, A., Maier, G.D., Young, M.E. Tumor responsiveness to the metastasis-stimulatory effects of prostaglandin E<sub>2</sub> is restricted by protein phosphatases. *Proceedings of the 3<sup>rd</sup> International Conference on Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Radiation Injury*, 1993.
4. **Young, M.R.I.** Human squamous cell carcinomas of the head and neck chemoattract CD34<sup>+</sup> progenitor cells and facilitate their differentiation into endothelial cells. *Proceedings on Head and Neck Cancer*, volume 5, pp. 127-132, 2000.
5. Lathers, D.M.R., Achille, N., **Young, M.R.I.** Dendritic cell development from mobilized peripheral blood CD34<sup>+</sup> cells. *In: Methods in Molecular Medicine – Cytokines and Colony Stimulating Factors*. D. Korholz (ed.), Humana Press Inc.- Totowa, NJ. P. 409-415, 2002.

#### **INVITED REVIEWS**

1. **Young, M.R.I.** Eicosanoids and the immunology of cancer. *Cancer Metastatic Reviews*, 13:337-348, 1994.
2. **Young, M.R.I.**, Lathers, D.M.R. Myeloid progenitor cells mediate immune suppression in patients with head and neck cancers. *Int. J. Immunopharmacol.*, 21: 241-252, 1999.
3. **Young, M.R.I.** Review of “Chemokines and Cancer”. *Ed: B. Rollins. Arch. Pathol. Lab. Med* 11: 43, 2000.
4. **Young, M.R.I.** Trials and tribulations of immunotherapy as a treatment option for patients with squamous cell carcinoma of the head and neck. Invited review. *Cancer Immunol. Immunother.*, 53: 375-382, 2004.

#### **SELECT PUBLISHED ABSTRACTS AND PRESENTATIONS (68 of 125):**

1. **Young, M.R.** and Young, M.E. The effect of recombinant murine interferon- $\gamma$  on the hematopoietic and immunological parameters of mice bearing metastatic Lewis lung carcinoma tumors. *Conf. on Immunity to Cancer*, Williamsburg, VA, November 9, 1987.
2. Wepsic, H.T., Duffie, G.P., Ellis, N.K., Romanelli, R.J. and **Young, M.R.** The effects of polyunsaturated fatty acids (PUFA) on graft vs. host disease (GvHD). *MidWest Autumn Immunol. Conf.*, Chicago, IL, November 16, 1987.

3. Sauter, D., **Young, M.R.**, Rahman, M. The effect of high eicosapentaenoic acid diet (EPA) on immune complex glomerulonephritis (ICGN) in the rat. *Kidney Int.*, 33: 285, 1988.
4. **Young, M.R.**, Young, M.E., and Wepsic, H.T. Effect of dietary fish oil on Lewis lung carcinoma-induced hematopoiesis, immune suppression, and immune suppressor cells. *FASEB J.*, 2: Abstract #3222, 1988.
5. **Young, M.R.**, and Young, M.E. The effect of recombinant murine interferon- $\gamma$  on the hematopoietic and immunological parameters of mice bearing metastatic Lewis lung carcinoma tumors. *Proc. Am. Assoc. Cancer Res.*, 29: Abstract #1453, 1988.
6. **Young, M.R.**, Young, M.E., and Kim, K. Tumor stimulation of myelopoiesis and the resultant appearance of bone marrow-derived immune suppressor cells. 2nd International Meeting of Anticancer Res., Saronis, Greece, October 13, 1988.
7. Young, M.E., **Young, M.R.**, and Kim, K. Lessening of myelopoiesis and the associated bone marrow-derived immune suppressor cells in tumor bearers by interferon- $\gamma$  and tumor necrosis factor- $\alpha$ . 2nd International Meeting of Anticancer Res., Saronis, Greece, October 13, 1988.
8. **Young, M.R.**, Young, M.E., and Kim, K. Regulation of tumor-induced myelopoiesis and the associated immune suppressor cells in mice bearing metastatic Lewis lung carcinomas by prostaglandin E<sub>2</sub>. *J. Leukocyte Biol.*, 44: Abstract #16, 1988.
9. **Young, M.R.**, and Young, M.E. Tumor-induced myelopoiesis and the associated immune suppressor cells. *FASEB J.*, 3: Abstract #1638, 1989.
10. **Young, M.R.**, Young, M.E., and Duffie, G.P. Prostaglandin E<sub>2</sub> responsiveness of Lewis lung carcinoma variants. *Proc. Am. Assoc. Cancer Res.*, 30: Abstract #342, 1989.
11. **Young, M.R.**, Young, M.E., and Wright, M.A. Interferon- $\gamma$  and tumor necrosis factor- $\alpha$  synergistically reduce myelopoiesis-associated immune suppressor cells in tumor bearers. *FASEB J.*, 4: Abstract #60094, 1990.
12. **Young, M.R.**, Young, M.E., and Wright, M.A. Stimulation of immune suppressive bone marrow cells by tumor factors and by colony stimulating factors. *Cancer Res.*, 50: Abstract #1787, 1990.
13. **Young, M.R.I.**, Young, M.E., and Wright, M.A. Stimulation of immune suppressor cells by tumor secretion of colony stimulating factors. *J. Leuko. Biol.*, 51: Abstract #76, 1990.
14. Bagash, J.M., **Young, M.R.I.** Regulation of c-myc expression in metastatic Lewis lung carcinoma cells by protein kinase. *FASEB J.*, 4: Abstract #2990, 1991.
15. **Young, M.R.I.**, Wright, M.A., Coogan, M. Tumor-derived GM-CSF and IL3 induce bone marrow suppressor cells which mediate immune suppression via IFN- $\alpha$  and TGF- $\beta$ . *FASEB J.*, 4: Abstract #6327, 1991.
16. **Young, M.R.**, Young, M.E., Wright, M.A. Prostaglandin E<sub>2</sub>-stimulated metastasis: mechanisms for hyperactivation of protein kinase A in metastatic vs. nonmetastatic Lewis lung carcinoma clones. *Proc. Am. Assoc. Cancer Res.*, 50: Abstract #398, 1991.

17. Kut, J.L., **Young**, M.R.I., Crayton, J.W., van de Kar, L., Arora, R.C. Regulation of murine T-lymphocyte function by endogenous serotonin. *Neuroscience*, Abstract #3039, 1991.
18. Azad, N., Emanuele, N.V., La Paglia, N., **Young**, M.R., Crayton, J.W., Lawrence, A.M. Epinephrine and norepinephrine effects on spleen lymphocyte blastogenesis. *Neuroscience*, 1991.
19. **Young**, M.R.I., Wright, M.A. Interferon- $\gamma$  plus tumor necrosis factor- $\alpha$  diminish the presence of tumor-induced bone marrow immune suppressor cells and reduce metastasis. *FASEB J.*, 6: Abstract #4362, 1992.
20. Bagash, J., **Young**, M.R.I. Modulation of metastasis in Lewis lung carcinoma cells by tumor necrosis factor- $\alpha$  and interferon- $\gamma$ . *FASEB J.*, 6: Abstract #2446, 1992.
21. Lozano, Y., Bagash, J., Young, M.E., Coogan, M., Wright, M.A., **Young**, M.R.I. Activation of protein kinase A stimulates tumor metastasis. *FASEB J.*, 6: Abstract #2448, 1992.
22. Wright, M.A., Bagash, J., **Young**, M.R.I. Tumor necrosis factor- $\alpha$  and interferon- $\gamma$  modulate the biological properties of Lewis lung carcinoma cells. *FASEB J.*, 6: Abstract #2447, 1992.
23. **Young**, M.R.I., Lozano, Y., Young, M.E., Wright, M.A., Coogan, M., Bagash, J. Stimulation of tumor metastasis by granulocyte-monocyte colony-stimulating factor. *Proc. Am. Assoc. Cancer Res.*, 52: Abstract #319, 1992.
24. Goto, M., Yoshioka, Y., **Young**, M.R.I., Gottschalk, M.E., Anderson, C.L., Zeller, W.P. Endotoxin tolerance in newborn rats. Conference on Shock, Santa Fe, New Mexico, 1993.
25. **Young**, M.R.I., Lozano, Y., Djordjevic, A., Devata, S., Matthews, J., Young, M.E., Wright, M.A. GM-CSF stimulates the metastatic properties of Lewis lung carcinoma cells through PKA signal transduction pathway. *FASEB J.*, Abstract #40074, 1993.
26. **Young**, M.R.I., Wright, M.A., Young, M.E., Matthews, J., Halpin, J. Immune suppressive GM-progenitor cells in GM-CSF-producing lung cancers. *J. Immunol*, 150: Abstract #495, 1993.
27. Azad, N., LaPaglia, N., Wright, M.A., Williams, D.W., Lawrence, A.M., **Young**, M.R. Luteinizing hormone releasing hormone (LHRH) decreases natural killer (NK) cell cytolytic activity. *Endocrine Society Meeting*, Abstract #1567, 1993.
28. **Young**, M.R.I., Lozano, Y., Djordjevic, A., Maier, G.D. Tumor responsiveness to the metastasis-stimulatory effects of prostaglandin E<sub>2</sub> is restricted by protein phosphatases. 3<sup>rd</sup> International Conference on Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Radiation Injury, Washington, D.C., 1993.
29. Gordon, P., Holland, L.E., **Young**, M.R.I. Suppression of HIV pathogenicity and apoptosis in lymphocytes by novel non-peptide inhibitors of protease. Selected for oral presentation at the 1<sup>st</sup> Int. Conf. on Applications of Apoptosis. La Jolla, California. 1994.

30. Roitman-Johnson, B., Southern, R.B., Kanabrocki, E.L., **Young**, R., Matthews, J., Yager, J.G., Krenz, M.M., Weatherbee, J.A., Scheving, L.E. Circadian characteristics of circulating interleukin-6 in non-atopic men. *Am. Acad. Allergy Immunol.* 1994.
31. Schmidt Pak, A., Wright, M.A., McCloskey, G., **Young**, M.R.I. Activation of CD8<sup>+</sup> tumor-infiltrating lymphocytes after eliminating immune suppressive granulocyte-macrophage progenitor cells. *Am. Assoc. Cancer Res.*, San Francisco, CA 1994.
32. **Young**, M.R.I., Schmidt Pak, A., Wright, M.A., Collins, S., Petruzzelli, G. Immune suppressive CD34<sup>+</sup> cells in human head and neck cancers. *FASEB J.*, Abstract #2737, 1994.
33. Roitman-Johnson, B., Southern, R.B., Kanabrocki, E.L., Yager, J.G., Roodell, M.M., Weatherbee, J.A., **Young**, M.R.I., Nemchausky, B.M., Shceving, L.E. Circadian characteristics of interleukin-6 in blood and urine of healthy adult men. *6th Int. Conf. Chronopharmacol. Chronother.* 1994.
34. Taitz, A., Petruzzelli, G., Pak, A., Wright, M.A., **Young**, M.R.I. Immune parameters of mice bearing human head & neck cancer. *Am. Assoc. Cancer Res.*, Toronto, Canada, 1995.
35. Kut, J.L., Matthews, J., Crayton, J.W., **Young**, M.R.I. The role of serotonin in human leukocyte function. *FASEB*, 1995.
36. **Young**, M.R.I., Lozano, Y., Wright, M.A., Djordjevic, A., Maier, G.D. Protein phosphatases-1 and -2A regulate tumor cell migration, invasion, and cytoskeletal organization. *Proceedings of the 4<sup>th</sup> International Meeting on Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Radiation Injury*, 1995.
37. Roitman-Johnson, B., Southern, R.B., Kanabrocki, E.L., Yager, J.G., Fuerstenberg, R.K., Weatherbee, J.A., **Young**, M.R.I., Nemchausky, B.M., Shceving, L.E. Comparison of circadian characteristics of interleukin-6 in blood and urine in human blood and urine. *J. Allergy Clin. Immunol.*, 95:365, 1995.
38. Southern, R.B., Roitman-Johnson, B., Kanabrocki, E.L., Yager, J.G., Fuerstenberg, R.K., Weatherbee, J.A., **Young**, M.R.I., Nemchausky, B.M., Shceving, L.E. Temporal & functional relationship between interleukin-6, leukocytes and serum cortisol in men. *J. Allergy Clin. Immunol.*, 95:375, 1995.
39. Lozano, Y., Maier, G.D., Vellody, K., Meisinger, J., **Young** M.R.I. Protein kinase A regulates tumor adherence to extracellular matrix components and metastasis. *Am. Assoc. Cancer Res.*, Washington D.C., 1996.
40. **Young**, M.R.I., Wright, M.A., Lozano, Y., Malik, I., Prechel, M.M. Suppression of T-cells by tumor-induced granulocyte-macrophage progenitor cells. *The FASEB J.*, 10: A1471, 1996.
41. Pandit, R., Wright, M., **Young**, M.R. Immunosuppressive CD34<sup>+</sup> cells in the peripheral blood of head and neck cancer patients. Abstract #809, *Am. Assoc. Cancer Res.*, San Diego, CA, 1997.

42. Donzelli, J., Leonetti, J.P., Bergstrom, B.S., Wurster, R.D., **Young**, M.R.I. Thermoprotective mechanisms of irrigation during bipolar cautery. 101<sup>st</sup> Meeting of the Am. Acad. Otolaryngology, San Francisco, Sept. 8, 1997.
43. Pandit, R., Wright, M.A., Garrity, T., **Young**, M.R.I. CD34<sup>+</sup> immune suppressor cells in the blood of head and neck cancer patients. 101<sup>st</sup> Meeting of the Am. Acad. Otolaryngology, San Francisco, Sept. 8, 1997.
44. Taitz, A., Benefield, J., Metz, R., Shankar, R., **Young**, M.R.I. Chemoattraction of squamous cell carcinomas to endothelial cells. 101<sup>st</sup> Meeting of the Am. Acad. Otolaryngology, San Francisco, Sept. 9, 1997.
45. Jackson, J.L., Meisinger, J.A., **Young**, M.R.I. Protein phosphatase 2A associates with microtubules and controls cellular adherence and motility in Lewis lung carcinoma tumor variants. Am. Assoc. Cancer Res., New Orleans, LA, 1998.
46. Messingham, K.N., Emami, B., **Young**, M.R.I. Local radiotherapy results in systemic monocyte activation in cancer patients. Am. Assoc. Cancer Res., New Orleans, LA, 1998.
47. Wy, C.A., Goto, M., **Young**, R., Myers, T.F. Prophylactic treatment of endotoxic shock with monophosphoryl lipid A in newborn rats. American Pediatric Soc./ Soc. Pediatric Res., 1999.
48. Lathers, D.R., Wright, M.A., **Young**, M.R.I. Differentiation of cancer induced CD34<sup>+</sup> cells. Abstract #248.5, Am. Assoc. Immunol. Meeting/Exp. Biol. '99, Washington D.C., 1999.
49. Messingham, K.A., **Young**, M.R.I. Macrophage function and response to gamma-radiation. Am. Assoc. Immunol. Meeting/Exp. Biol. '99, Washington D.C., 1999.
50. Gabel, S., Benefield, J., Mesinger, J., Petruzzelli, G.J., **Young**, M.R.I. Protein phosphatases-1 and -2A maintain endothelial cells in a resting state, limiting the motility that is needed for the morphogenic process of angiogenesis. 1999 Annual Meeting, Am. Acad. Otolaryngol. - Head and Neck Cancer, New Orleans, 1999.
51. **Young**, M.R.I., Beal, N., Lingen, N.W., Gabrilovich, D.I. Contribution of vasculogenesis to tumor vascularization. Abstract #556, Am. Assoc. Cancer Res., San Francisco, CA, 2000.
52. Lathers, D.M.R., Beal, N.M., Clark, J., **Young**, M.R.I. Treatment of cancer patients with 25-hydroxyvitamin D<sub>3</sub> to improve immune function. Am. Assoc. Immunol. Meeting, Seattle, WA, 2000.
53. **Young**, M.R.I., Lingen, M.W., Gabrilovich, D.I. Contribution of CD34<sup>+</sup> progenitor cells to tumor vascularization. Abstract # PA356. 5<sup>th</sup> Int. Conf. Head and Neck Cancer, San Francisco, CA, 2000.
54. Shafer, L.L., **Young**, M.R.I., McNulty, J. IL-10 mimics the differential response of brain cocultures on activation of a microglial cell line. 30<sup>th</sup> Annual Meeting, Soc. Neurosci., New Orleans, LA, 2000.

55. **Young, M.R.I.,** Lathers, D.M.R., Achille, N., Kolesiak, K., Petruzzelli, J.G. Immunotherapy for head and neck cancers based on the conversion of tumor-mobilized immune inhibitory progenitor cells into antigen-presenting dendritic cells. Abstract #516, 11<sup>th</sup> International Congress for Immunology, Stockholm, 2001.
56. Wachter, B.G., Leonetti, J.P., Lee, J.M., Wurster, R.D., **Young, M.R.I.** Silver nitrate injury in the rat sciatic nerve: A model of facial nerve injury. 2001 Annual Meeting, Am. Acad. Otolaryngol. - Head and Neck Cancer, Denver, 2001.
55. Kolesiak, K., Achille, N., Lathers, D.M.R., Gabrilovich, D., Petruzzelli G.J., **Young, M.R.I.** Head and neck squamous cell carcinomas chemoattract immune suppressive CD34<sup>+</sup> cells. Lung Cancer, 34: \$55, 2001.
56. Kanabrocki, E.L., Ryan, M.D., Hermida, R.C., Ayala, D.E., Lathers, D., Achille, N., **Young, M.R.I.,** Bremner, W.F., Third, J.L.H.C., Shirazi, P., Siegel, G., Nemchausky, B.A., Hooper, D.C. Disconnected variables in blood and urine in multiple sclerosis patients. Chronobiol. Int., 18:1136-1137, 2001.
57. Lathers, D.M.R., Clark, J.J., Achille, N.J., **Young, M.R.I.** Phase 1B trial treating cancer patients with 25-hydroxyvitamin D<sub>3</sub> to improve immune function. Lung Cancer, 34: \$55, 2001.
58. Lathers, D.M.R., Clark, J.J., Achille, N.J., **Young, M.R.I.** Phase 1B trial treating cancer patients with 25-hydroxyvitamin D<sub>3</sub> to improve immune function. Am. Assoc. Immunol. Meeting/Exp. Biol. '02, Abstract LB485, New Orleans, 2002.
59. **Young, M.R.I.,** Kolesiak, K., Meisinger, J., Liu, S. Crossover between serine phosphatase and tyrosine kinase pathways that regulate angiogenesis. Abstract # 121, Am. Head Neck Soc., Abstract 278, McLean VA, 2002.
60. Lathers, D.M.R., Achille, N.J., Bier-Laning, C., Petruzzelli, G.J., **Young, M.R.I.** Plasma levels of immune modulating cytokines in head and neck squamous cell carcinoma patients. Abstract #040, Am. Head Neck Soc., Abstract 278, McLean VA, 2002.
61. Bier-Laning, C.M., Schroeder, M., **Young, M.R.I.** Cellular invasion differences are associated with differences in FAK and Src in normal keratinocytes versus malignant squamous cells. Abstract #074, Am. Head Neck Soc., Abstract 278, McLean VA, 2002.
62. Lathers, D.M.R., Clark, J.I., Achille, N.J., **Young, M.R.I.** Phase 1B trial treating head and neck cancer patients with 25-hydroxyvitamin D<sub>3</sub> to improve immune function. Abstract # 0142, Am. Head Neck Soc., Abstract 278, McLean VA, 2002.
63. Lathers, D.M.R., Achille, N.J., **Young, M.R.I.** Plasma levels of immune modulating cytokines in head and neck squamous cell carcinoma patients. Abstract #1702, Am. Assoc. Immunol., Denver, CO, 2003.
64. Young, M.R.I. Prevention and treatment of head and neck cancer: from laboratory to clinic. Invited talk for the Charleston Swallowing Conference, January 31, 2004.
65. Young, M.R.I. Tumor blood vessel development by vasculogenesis, not only angiogenesis. Am. Assoc. Immunol. Meeting/Exp. Biol. '04, Abstract 2663, Washington D.C., April 21, 2004.

66. Block, M.I., Blanton, M.G., Lathers, D.M.R., Young, M.R.I. STAT4 and STAT6 regulate naïve CD8 cell type 1 but not type 2 cytokine production. 12<sup>th</sup> Int. Congress of Immunol., Montreal, Canada, 2004.
67. Young, M.R. CD34<sup>+</sup> cells of cancer patients - from immune suppression to tumor vascularization. Grand Rounds, Department of Medicine, Medical University of South Carolina. July 27, 2004.

**MANUSCRIPT CURRENTLY UNDER REVIEW:**